Lantheus (NASDAQ:LNTH) Issues Earnings Results

Lantheus (NASDAQ:LNTH) released its quarterly earnings results on Thursday. The medical equipment provider reported $1.27 earnings per share for the quarter, meeting the consensus estimate of $1.27, Briefing.com reports. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $384.01 million for the quarter, compared to analysts’ expectations of $363.42 million. During the same period in the prior year, the firm earned $1.70 EPS. The company’s revenue was up 1.4% compared to the same quarter last year. Lantheus updated its FY 2025 guidance to 5.500-5.650 EPS.

Lantheus Price Performance

Shares of LNTH traded down $2.62 during mid-day trading on Friday, reaching $51.07. The stock had a trading volume of 1,757,334 shares, compared to its average volume of 1,261,428. The business has a fifty day moving average of $54.09 and a 200 day moving average of $68.72. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The firm has a market cap of $3.47 billion, a price-to-earnings ratio of 13.58 and a beta of 0.04. Lantheus has a 12 month low of $47.25 and a 12 month high of $111.29.

Wall Street Analyst Weigh In

Several brokerages have issued reports on LNTH. Truist Financial set a $63.00 target price on Lantheus and gave the stock a “hold” rating in a research report on Monday, August 11th. The Goldman Sachs Group set a $77.00 price objective on shares of Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Mizuho cut their target price on shares of Lantheus from $120.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, August 7th. William Blair reaffirmed a “market perform” rating on shares of Lantheus in a report on Wednesday, July 16th. Finally, TD Cowen decreased their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Four equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $74.50.

Insider Buying and Selling at Lantheus

In related news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of the stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company’s stock, valued at $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 6,812,000 shares of company stock worth $382,427,380 over the last 90 days. Insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. lifted its holdings in Lantheus by 25.1% in the 2nd quarter. Raymond James Financial Inc. now owns 470,678 shares of the medical equipment provider’s stock worth $38,530,000 after purchasing an additional 94,312 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its holdings in Lantheus by 191.5% in the 2nd quarter. BI Asset Management Fondsmaeglerselskab A S now owns 97,958 shares of the medical equipment provider’s stock valued at $8,019,000 after acquiring an additional 64,358 shares during the last quarter. First Light Asset Management LLC bought a new position in shares of Lantheus during the 2nd quarter valued at about $2,459,000. Vident Advisory LLC boosted its holdings in shares of Lantheus by 46.7% during the 2nd quarter. Vident Advisory LLC now owns 69,575 shares of the medical equipment provider’s stock valued at $5,695,000 after purchasing an additional 22,148 shares during the last quarter. Finally, First Trust Advisors LP grew its position in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after purchasing an additional 19,008 shares in the last quarter. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.